Get the Stockscreener App
5.706
3.14%
-0.189
Replimune Group Inc stock is traded at $5.706, with a volume of 877.73K.
It is down -3.14% in the last 24 hours and up +0.00% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$5.895
Open:
$5.76
24h Volume:
877.73K
Relative Volume:
0.11
Market Cap:
$445.31M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-1.8057
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+6.13%
1M Performance:
+0.00%
6M Performance:
-52.50%
1Y Performance:
-45.31%
1-Day Range:
$5.65
$5.87
1-Week Range:
$5.33
$6.1499
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.705 | 460.53M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.10 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.17 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.12 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
731.25 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.81 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune's Regulatory Setback and Legal Exposure: A Cautionary Tale for Biotech Investors - AInvest
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug ApprovalHagens Berman - PR Newswire
Replimune Group Inc. stock trend outlook and recovery pathLong Setup & Expert Approved Momentum Trade Ideas - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline September 22, 2025 - ACCESS Newswire
Will Replimune Group Inc. continue its uptrendLong Setup & Real-Time Chart Breakout Alerts - Newser
Ranking Replimune Group Inc. among high performing stocks via toolsGap Up & Growth Focused Stock Reports - Newser
Real time alert setup for Replimune Group Inc. performance2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
American Century Companies Inc. Grows Stake in Replimune Group, Inc. $REPL - Defense World
Developing predictive dashboards with Replimune Group Inc. dataJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Replimune’s Regulatory Crossroads: Can RP1 Navigate FDA Hurdles in Advanced Melanoma? - AInvest
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Can you recover from losses in Replimune Group Inc.July 2025 Breakouts & Free Community Consensus Stock Picks - Newser
Risk vs reward if holding onto Replimune Group Inc.2025 Retail Activity & Precise Swing Trade Entry Alerts - Newser
Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha
What Fibonacci levels say about Replimune Group Inc. reboundMarket Risk Report & Real-Time Buy Signal Alerts - Newser
What’s the recovery path for long term holders of Replimune Group Inc.Trade Ideas & Daily Profit Maximizing Tips - Newser
Full technical analysis of Replimune Group Inc. stockQuarterly Earnings Summary & Verified Stock Trade Ideas - Newser
What MACD signals say about Replimune Group Inc.Index Update & Consistent Growth Equity Picks - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key DrugHagens Berman - GlobeNewswire
Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREPL - WV News
Replimune Announces Type A Meeting Scheduled with FDA - The Manila Times
Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment - Stock Titan
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Detecting support and resistance levels for Replimune Group Inc.Market Activity Summary & AI Driven Stock Price Forecasts - Newser
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
Class Action Lawsuit Filed: Replimune Group, Inc. (REPL)Join by September 22, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Can Replimune Group Inc. continue delivering strong returnsQuarterly Market Summary & Proven Capital Preservation Tips - خودرو بانک
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
News impact scoring models applied to Replimune Group Inc.Portfolio Update Report & Weekly Setup with High ROI Potential - Newser
Kessler Topaz Meltzer & Check, LLP Encourages Replimune Group, Inc. Investors With Losses to Contact the Firm - NewMediaWire
Identifying reversal signals in Replimune Group Inc.July 2025 Selloffs & Verified Momentum Stock Ideas - Newser
Replimune Group Inc. Builds Base for Possible Rebound getLinesFromResByArray error: size == 0 - thegnnews.com
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
How to build a dashboard for Replimune Group Inc. stockPrice Action & AI Driven Stock Movement Reports - Newser
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL | FinancialContent - FinancialContent
REPL Class Action Lawsuit Reminder: Kessler Topaz Meltzer & - GlobeNewswire
Replimune Group Inc. stock prediction for this weekMarket Growth Summary & Stock Portfolio Risk Control - Newser
REPL Class Action Reminder: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Replimune Group, Inc. Class Action Lawsuit - Morningstar
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
1.37%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):